Barclays raised the firm’s price target on Boston Scientific (BSX) to $136 from $133 and keeps an Overweight rating on the shares. The company issued an “impressive” three-year plan with organic growth of 10%, driving by a broad array of growth programs, the analyst tells investors in a research note. The firm sees “significant upside” for Boston Scientific shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Top 3 Trending Stocks, According to Analysts – 10/1/2025
- Boston Scientific call volume above normal and directionally bullish
- Boston Scientific price target raised to $129 from $125 at Truist
- Elutia closes sale of its BioEnvelope business to Boston Scientific for $88M
- Boston Scientific price target raised to $132 from $127 at BTIG